(2,5-dibromophenyl)(4-ethoxyphenyl)methanone is an impurity of Dapagliflozin. Dapagliflozin is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2) in development for the treatment of type 2 diabetes mellitus (T2DM).